| 4.11 -0.12 (-2.84%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.2 |
1-year : | 5.6 |
| Resists | First : | 4.45 |
Second : | 4.8 |
| Pivot price | 4.14 |
|||
| Supports | First : | 3.89 | Second : | 3.23 |
| MAs | MA(5) : | 4.14 |
MA(20) : | 4.19 |
| MA(100) : | 4.4  |
MA(250) : | 3.74 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 59.7 |
D(3) : | 54.6 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 5.46 | Low : | 1.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORMP ] has closed above bottom band by 34.1%. Bollinger Bands are 72% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.25 - 4.27 | 4.27 - 4.29 |
| Low: | 4.02 - 4.05 | 4.05 - 4.07 |
| Close: | 4.07 - 4.11 | 4.11 - 4.15 |
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Fri, 30 Oct 2026
Oramed Pharmaceuticals Inc. (ORMP) Seasonal Returns Chart - Yahoo! Finance Canada
Fri, 23 Oct 2026
Oramed Pharmaceuticals Inc. Estimates – NASDAQ:ORMP - TradingView
Thu, 01 Oct 2026
An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan. - Stock Titan
Fri, 11 Sep 2026
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Thu, 13 Aug 2026
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - kalkine.ca
Sat, 25 Jul 2026
Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 45 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 1,150 (K) |
| EPS | 4.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -3.5 % |
| Return on Equity (ttm) | 74.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 493.5 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 0.99 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -32.82 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|